CO66 Reduction in Migraine-Associated Burden over 24 Weeks of Treatment with Eptinezumab in Patients with Chronic Migraine
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.164
https://www.valueinhealthjournal.com/article/S1098-3015(22)00365-5/fulltext
Title :
CO66 Reduction in Migraine-Associated Burden over 24 Weeks of Treatment with Eptinezumab in Patients with Chronic Migraine
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00365-5&doi=10.1016/j.jval.2022.04.164
First page :
Section Title :
Open access? :
No
Section Order :
10137